BidaskClub upgraded shares of RadNet (NASDAQ:RDNT) from a sell rating to a hold rating in a research note issued to investors on Saturday.
A number of other research analysts also recently weighed in on RDNT. Zacks Investment Research downgraded RadNet from a hold rating to a sell rating in a report on Wednesday, October 4th. TheStreet downgraded RadNet from a b- rating to a c rating in a report on Friday, October 27th.
RadNet (NASDAQ RDNT) opened at $10.15 on Friday. RadNet has a 1-year low of $5.25 and a 1-year high of $11.90. The company has a debt-to-equity ratio of 7.88, a current ratio of 1.29 and a quick ratio of 1.29. The firm has a market capitalization of $483.38, a PE ratio of 44.13, a price-to-earnings-growth ratio of 2.31 and a beta of 0.83.
RadNet (NASDAQ:RDNT) last posted its earnings results on Thursday, November 9th. The medical research company reported $0.12 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.12. RadNet had a return on equity of 23.73% and a net margin of 1.21%. The company had revenue of $227.60 million for the quarter, compared to the consensus estimate of $232.84 million. During the same quarter in the prior year, the company earned $0.11 earnings per share. RadNet’s revenue was up 1.3% on a year-over-year basis. equities research analysts forecast that RadNet will post 0.35 EPS for the current year.
In other RadNet news, Director John V. Crues sold 20,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $10.08, for a total value of $201,600.00. Following the completion of the sale, the director now owns 563,781 shares in the company, valued at $5,682,912.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Norman R. Hames sold 5,000 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the completion of the sale, the insider now owns 407,257 shares of the company’s stock, valued at approximately $4,072,570. The disclosure for this sale can be found here. In the last three months, insiders sold 133,084 shares of company stock worth $1,321,587. 9.36% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of RDNT. Airain ltd purchased a new stake in RadNet in the second quarter worth about $100,000. Prudential Financial Inc. increased its position in RadNet by 15.2% in the second quarter. Prudential Financial Inc. now owns 20,410 shares of the medical research company’s stock worth $158,000 after buying an additional 2,700 shares in the last quarter. Parallax Volatility Advisers L.P. increased its position in RadNet by 122.0% in the second quarter. Parallax Volatility Advisers L.P. now owns 21,122 shares of the medical research company’s stock worth $164,000 after buying an additional 117,148 shares in the last quarter. Voya Investment Management LLC increased its position in RadNet by 19.5% in the second quarter. Voya Investment Management LLC now owns 21,726 shares of the medical research company’s stock worth $168,000 after buying an additional 3,546 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in RadNet in the third quarter worth about $195,000. Institutional investors and hedge funds own 53.16% of the company’s stock.
WARNING: “RadNet (RDNT) Stock Rating Upgraded by BidaskClub” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/10/radnet-rdnt-stock-rating-upgraded-by-bidaskclub.html.
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.